Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Enterovirus 71 (HEV71) epidemics in children and infants result mainly in mild symptoms; however, especially in the Asia-Pacific region, infection can be fatal. At present, no therapies are available. We have used structural analysis of the complete virus to guide the design of HEV71 inhibitors. Analysis of complexes with four 3-(4-pyridyl)-2-imidazolidinone derivatives with varying anti-HEV71 activities pinpointed key structure-activity correlates. We then identified additional potentially beneficial substitutions, developed methods to reliably triage compounds by quantum mechanics-enhanced ligand docking and synthesized two candidates. Structural analysis and in vitro assays confirmed the predicted binding modes and their ability to block viral infection. One ligand (with IC50 of 25 pM) is an order of magnitude more potent than the best previously reported inhibitor and is also more soluble. Our approach may be useful in the design of effective drugs for enterovirus infections.

Original publication

DOI

10.1038/nsmb.2769

Type

Journal article

Journal

Nat Struct Mol Biol

Publication Date

03/2014

Volume

21

Pages

282 - 288

Keywords

Antiviral Agents, Binding Sites, Capsid, Capsid Proteins, Chemistry, Pharmaceutical, Drug Design, Enterovirus A, Human, Enterovirus Infections, Imidazoles, Inhibitory Concentration 50, Ligands, Protein Binding, Protein Conformation, Structure-Activity Relationship